Levobel

Ethinylestradiol and Levonorgestrel, the active ingredients in Levobel, are a combined oral contraceptive presented as a tablet for oral use. This estrogen‑progestin formulation prevents pregnancy by suppressing ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Levobel as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide, providing reliable access to EU‑approved hormonal contraceptives. The company adheres to stringent quality standards and regulatory compliance to meet the needs of healthcare providers across global markets.

Levobel, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

Prevention of pregnancy: provides reliable contraception for women of reproductive age. Menstrual cycle regulation: helps achieve more predictable bleeding patterns. Moderate acne management: reduces androgenic activity contributing to acne lesions.

Levobel may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset often occurring early in the cycle. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding between periods. - Weight gain: mild fluid retention or increased appetite.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Hypertensive disorders: significant rise in blood pressure or stroke risk. - Hepatic adenoma: rare benign liver tumor. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Before prescribing Levobel, clinicians should evaluate several safety considerations to minimise risk.

Cardiovascular risk: assess history of thromboembolic events, smoking, or hypertension. Liver function: avoid use in patients with active liver disease or severe hepatic impairment. Migraine history: contraindicated in women with migraine with aura. Smoking status: limit use in smokers over 35 years of age due to increased clot risk. Concomitant medications: review drugs that may affect hormone metabolism. Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Levobel can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may reduce anticoagulant effect, increasing clot risk. - Certain antiepileptics (e.g., carbamazepine, phenytoin): induce hepatic enzymes, decreasing contraceptive efficacy. - Rifampicin and other strong enzyme inducers: markedly lower hormone levels, risking contraceptive failure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect potential. - HIV protease inhibitors: can alter hormone metabolism, requiring monitoring. - St. John’s wort: may modestly reduce contraceptive effectiveness.